Castle Biosciences (CSTL) Operating Leases (2021 - 2026)
Castle Biosciences' Operating Leases history spans 5 years, with the latest figure at $25.2 million for Q4 2025.
- On a quarterly basis, Operating Leases rose 75.79% to $25.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.2 million, a 75.79% increase, with the full-year FY2025 number at $25.2 million, up 75.79% from a year prior.
- Operating Leases hit $25.2 million in Q4 2025 for Castle Biosciences, roughly flat from $25.3 million in the prior quarter.
- Over the last five years, Operating Leases for CSTL hit a ceiling of $25.4 million in Q2 2025 and a floor of $6.5 million in Q2 2022.
- Historically, Operating Leases has averaged $14.2 million across 5 years, with a median of $13.6 million in 2024.
- Biggest five-year swings in Operating Leases: soared 91.77% in 2023 and later increased 1.21% in 2024.
- Tracing CSTL's Operating Leases over 5 years: stood at $6.9 million in 2021, then skyrocketed by 67.14% to $11.5 million in 2022, then grew by 22.89% to $14.2 million in 2023, then increased by 1.21% to $14.3 million in 2024, then surged by 75.79% to $25.2 million in 2025.
- Business Quant data shows Operating Leases for CSTL at $25.2 million in Q4 2025, $25.3 million in Q3 2025, and $25.4 million in Q2 2025.